Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2021 | NSCLC | Original Article

18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer

Authors: Fengxian Zhang, Xiaodong Wu, Junjie Zhu, Yan Huang, Xiao Song, Lei Jiang

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2021

Abstract

Purpose

This study retrospectively investigated the clinical utility of 2-deoxy-18F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) and circulating tumor cells (CTCs) in the diagnosis and prognosis of treatment-naive patients with non-small-cell lung cancer (NSCLC).

Methods

The blood samples of treatment-naive patients with NSCLC were collected for CTCs detection, and the tumor metabolic parameters of ¹⁸F-FDG PET/CT, including maximum standard uptake value (SUVmax), metabolic tumor volume of primary lesion (MTV-P) and combination of primary lesion and metastases (MTV-C), and total lesion glycolysis of primary lesion (TLG-P) and combination of primary lesion and metastases (TLG-C), were analyzed. Age, sex, smoking, serum tumor markers, tumor size, location, TNM stage, and genetic mutations were also reviewed. Moreover, progression-free survival (PFS) and overall survival (OS) of these patients were analyzed.

Results

A total of 309 patients with NSCLC (200 men, 109 women; mean age: 61 ± 9 years) were enrolled in this study, including 217 patients with adenocarcinoma and 92 with squamous cell carcinoma. Of the 309 cases, 11 were misdiagnosed with benign diseases by ¹⁸F-FDG PET/CT. CTCs positivity was detected in 234 cases. The sensitivity of ¹⁸F-FDG PET/CT and CTCs in NSCLC were 96.4% and 75.7%, respectively. SUVmax, MTV-P, TLG-P, MTV-C, TLG-C, tumor size, and serum CYFRA211 levels were significantly higher in CTCs positive group than negative group; and advanced TNM stage, squamous cell carcinoma, and EGFR wild type presented higher CTCs positivity. Multivariate logistic regression analysis revealed that SUVmax was significantly associated with CTCs positivity. Multivariate cox regression analysis showed that TLG-P, TLG-C, and CTCs were independent predictors of PFS in patients with NSCLC, and TLG-C and CTCs were independent predictors of OS.

Conclusions

¹⁸F-FDG PET/CT was superior to CTCs in the diagnosis of treatment-naive patients with NSCLC. The levels of CTCs in the peripheral blood were associated with tumor glucose metabolism in NSCLC. Metabolic parameters of ¹⁸F-FDG PET/CT and CTCs could separately predict the outcomes of treatment-naive patients with NSCLC.

Available only for authorised users

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. https://doi.org/10.3322/caac.21166.CrossRefPubMed

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England). 2018;391:1023–75. https://doi.org/10.1016/s0140-6736(17)33326-3.CrossRefPubMedCentral

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18:2391–401. https://doi.org/10.1158/1078-0432.Ccr-11-3148.CrossRefPubMed

Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. https://doi.org/10.1097/JTO.0b013e31812f3c1a.CrossRefPubMed

Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. Cancer Treat Res. 2016;170:47–75. https://doi.org/10.1007/978-3-319-40389-2_3.CrossRefPubMed

Yu B, Zhu X, Liang Z, Sun Y, Zhao W, Chen K. Clinical usefulness of (18)F-FDG PET/CT for the detection of distant metastases in patients with non-small cell lung cancer at initial staging: a meta-analysis. Cancer Manag Res. 2018;10:1859–64. https://doi.org/10.2147/cmar.S155542.CrossRefPubMedPubMedCentral

Kandathil A, Kay FU, Butt YM, Wachsmann JW, Subramaniam RM. Role of FDG PET/CT in the eighth edition of TNM staging of non-small cell lung cancer. Radiographics. 2018;38:2134–49. https://doi.org/10.1148/rg.2018180060.CrossRefPubMed

Sharma A, Mohan A, Bhalla AS, Vishnubhatla S, Pandey AK, Bal CS, et al. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer. Nucl Med Commun. 2017;38:858–67. https://doi.org/10.1097/mnm.0000000000000723.CrossRefPubMed

Kanyilmaz G, Benli Yavuz B, Aktan M, Sahin O. Prognostic importance of (18)F-fluorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy. Rev Esp Med Nucl Imagen Mol. 2020;39:20–6. https://doi.org/10.1016/j.remn.2019.04.006.CrossRefPubMed

10.

Bayarri-Lara CI, de Miguel PD, Cueto Ladron de Guevara A, Rodriguez Fernandez A, Puche JL, Sanchez-Palencia Ramos A, et al. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers. Eur J Cardiothorac Surg. 2017;52:55–62. https://doi.org/10.1093/ejcts/ezx049.CrossRefPubMed

11.

Fu L, Zhu Y, Jing W, Guo D, Kong L, Yu J. Incorporation of circulating tumor cells and whole-body metabolic tumor volume of (18)F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer. Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu. 2018;30:596–604. https://doi.org/10.21147/j.issn.1000-9604.2018.06.04.CrossRefPubMed

12.

Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–91. https://doi.org/10.1158/2159-8290.Cd-15-1483.CrossRefPubMed

13.

Gallo M, De Luca A, Maiello MR, D’Alessio A, Esposito C, Chicchinelli N, et al. Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Transl Lung Cancer Res. 2017;6:486–98. https://doi.org/10.21037/tlcr.2017.05.07.CrossRefPubMedPubMedCentral

14.

Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623–31. https://doi.org/10.1038/nrc3820.CrossRefPubMed

15.

Wu X, Huang Y, Li Y, Wang Q, Wang H, Jiang L. (18)F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings. Ann Nucl Med. 2019;33:647–56. https://doi.org/10.1007/s12149-019-01374-5.CrossRefPubMed

16.

Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, et al. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One. 2013;8:e67733. https://doi.org/10.1371/journal.pone.0067733.CrossRefPubMedPubMedCentral

17.

Castello A, Carbone FG, Rossi S, Monterisi S, Federico D, Toschi L, et al. Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors. Cancers. 2020;12. https://doi.org/10.3390/cancers12020487.

18.

Bian J, Yan K, Liu N, Xu X. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer. J Cancer Res Clin Oncol. 2020;146:2621–30. https://doi.org/10.1007/s00432-020-03244-4.CrossRefPubMed

19.

Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526–33. https://doi.org/10.1148/radiol.2292021598.CrossRefPubMed

20.

Yi CA, Lee KS, Kim BT, Choi JY, Kwon OJ, Kim H, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med. 2006;47:443–50.PubMed

21.

Cheng G, Huang H. Prognostic value of (18)F-Fluorodeoxyglucose PET/computed tomography in non-small-cell lung cancer. PET Clin. 2018;13:59–72. https://doi.org/10.1016/j.cpet.2017.08.006.CrossRefPubMed

22.

Kim DH, Song BI, Hong CM, Jeong SY, Lee SW, Lee J, et al. Metabolic parameters using (1)(8)F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2051–7. https://doi.org/10.1007/s00259-014-2831-6.CrossRefPubMed

23.

Ito R, Iwano S, Kishimoto M, Ito S, Kato K, Naganawa S. Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma? Ann Nucl Med. 2015;29:897–905. https://doi.org/10.1007/s12149-015-1025-z.CrossRefPubMed

24.

Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, et al. Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer: (18)F-FDG PET/CT study. J Nucl Med. 2017;58:1764–9. https://doi.org/10.2967/jnumed.117.193201.CrossRefPubMed

25.

Dong J, Zhu D, Tang X, Lu D, Qiu X, Li B, et al. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. PLoS One. 2019;14:e0220306. https://doi.org/10.1371/journal.pone.0220306.CrossRefPubMedPubMedCentral

26.

Gao W, Yuan H, Jing F, Wu S, Zhou H, Mao H, et al. Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip. Oncotarget. 2017;8:12917–28. https://doi.org/10.18632/oncotarget.14203.CrossRefPubMed

27.

Chu XY, Hou XB, Song WA, Xue ZQ, Wang B, Zhang LB. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis. Cancer Biol Ther. 2011;11:995–1000. https://doi.org/10.4161/cbt.11.12.15526.CrossRefPubMed

28.

Fu L, Wang R, Yin L, Shang X, Zhang R, Zhang P. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis. Int J Biol Markers. 2019;34:251–61. https://doi.org/10.1177/1724600819868234.CrossRefPubMed

29.

Wei T, Zhu D, Yang Y, Yuan G, Xie H, Shen R. The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment. PLoS One. 2019;14:e0219129. https://doi.org/10.1371/journal.pone.0219129.CrossRefPubMedPubMedCentral

30.

Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559–66. https://doi.org/10.1148/radiol.12111148.CrossRefPubMed

31.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27–38. https://doi.org/10.1007/s00259-011-1934-6.CrossRefPubMed

32.

Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011;17:827–35. https://doi.org/10.1158/1078-0432.Ccr-10-0445.CrossRefPubMed

33.

Isobe K, Hata Y, Kobayashi K, Hirota N, Sato K, Sano G, et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res. 2012;32:3339–44.PubMed

Title: 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer
Authors: Fengxian Zhang
Xiaodong Wu
Junjie Zhu
Yan Huang
Xiao Song
Lei Jiang
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
Lung Cancer
Lung Cancer
NSCLC
Lung Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05260-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2021

RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

Diagnostic performance of preoperative [18F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study

Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging

Weakly supervised deep learning for determining the prognostic value of 18F-FDG PET/CT in extranodal natural killer/T cell lymphoma, nasal type